Protalix announces FDA and EU approval of Elfabrio for Fabry disease; investor event June 27

Protalix BioTherapeutics, Inc.

Elfabrio (pegunigalsidase alfa) approved in both US and EU for adult Fabry disease patients.
Commercial partner Chiesi Global Rare Diseases is prepared for launch.
In-person investor event scheduled for June 27, 2023 at Lotte Palace Hotel, New York City.
CEO Dror Bashan highlights ProCellEx platform and pipeline programs for future growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.